hit counter
Anavex Life Sciences Corp. (AVXL) Stock News Sentiment & Price - Sentifly
AVXL - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Anavex Life Sciences Corp. (AVXL)

USA
Biotechnology
NASDAQ
AVXL Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AVXL Latest news
The Motley Fool
Positive
2 Biotech Stocks Set to Go Supernova Soon
2021-10-18 07:45

Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

Seeking Alpha
Neutral
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
2021-10-16 07:30

Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed.

GlobeNewsWire
Neutral
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
2021-10-15 07:00

NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the Dawson James Securities 6th Annual Conference on Thursday, October 21, 2021 at 1:30 PM (ET).

GlobeNewsWire
Neutral
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
2021-09-27 09:30

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join a panel discussion titled, “Fragile X Syndrome Case Study: From Preclinical to Clinical, Making Drug Development Efficient through Community-based Collaboration” at the 5th Pharma Pricing, Reimbursement & Market Access 2021 conference on Wednesday, September 29th at 2:40 pm ET.

GlobeNewsWire
Neutral
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
2021-09-27 07:00

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that effective as of market open today, September 27, 2021, its shares of common stock have been approved for uplisting to the NASDAQ Global Select Market® and will continue trading under its current ticker symbol AVXL.

GlobeNewsWire
Neutral
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
2021-09-20 07:00

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 10:40 AM (ET). The conference is being held September 27-30, 2021.

Seeking Alpha
Positive
Anavex Life Sciences: Still Room To Run
2021-08-29 08:11

Lead candidate ANAVEX2-73 has shown impressive results in placebo-controlled Phase 2 studies in Parkinson's disease and Rett syndrome. Ongoing studies in Rett syndrome could lead to a filing in 2022 if results are positive.

Seeking Alpha
Neutral
Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript
2021-08-12 23:18

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q3 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
2021-08-12 07:00

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2021.

InvestorPlace
Positive
Use Weakness in these 3 Alzheimer's Disease Stocks as Opportunity
2021-08-10 10:49

Millions of Americans are struggling with Alzheimer's, according to the Alzheimer's Association. The disease often has a slow progression, lasting years or even decades, and it's one of the leading causes of death in the United States.

Loading more news...